<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755855</url>
  </required_header>
  <id_info>
    <org_study_id>20-010181</org_study_id>
    <nct_id>NCT04755855</nct_id>
  </id_info>
  <brief_title>Prospective Sinonasal Cancer Multi-institution Study</brief_title>
  <official_title>Sinonasal Cancer Study to Evaluate Oncologic Outcomes and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-institution prospective study of patients with sinonasal malignancies. The&#xD;
      goal of this study is to learn more about the course of sinonasal cancer, treatment outcomes,&#xD;
      and patient quality of life. In addition, central mutational and genomic analysis of tumor&#xD;
      tissue will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2031</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2031</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oncologic outcomes as measured by overall survival, disease specific survival and recurrence free survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life outcomes including the University of Washington Quality of Life Questionnaire (UW-QOL v4) and the Sinonasal Outcome Test 22 (SNOT22)</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the molecular foundation of sinonasal malignancies utilizing RNA sequencing to identify transcriptomic tumor profiles</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sinonasal Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing treatment for sinonasal cancers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects between the ages of 30 days (non-inclusive) and 99 years (inclusive)&#xD;
&#xD;
          -  Patients with a diagnosis of sinonasal cancer&#xD;
&#xD;
          -  Patients undergoing treatment at Mayo Clinic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Healthy individuals&#xD;
&#xD;
          -  Unwilling to sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garret W Choby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marissa Larson</last_name>
    <phone>(507) 216-4999</phone>
    <email>larson.marissa@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Garret W. Choby</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

